Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
P/B ratio for Idorsia Ltd (IDIA.SW)
P/B ratio as of 2023: -0.39
According to Idorsia Ltd's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -0.39. At the end of 2022 the company had a P/B ratio of -3.60.
P/B ratio history for Idorsia Ltd from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -0.39 |
| 2022 | -3.60 |
| 2021 | 30.14 |
| 2020 | 6.22 |
| 2019 | 23.08 |
| 2018 | 3.26 |
| 2017 | 3.94 |
| 2016 | 3.17 |